Physician profile

Morgan E Norris

Plastic and Reconstructive Surgery · Houston, TX

NPI 1902986656

$1,400.32

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$346.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mentor Worldwide LLC $282.52 2019-2021
Davol INC. $269.62 2022
Allergan, INC. $186.87 2019-2021
Tela Bio, INC. $179.84 2022-2024 Ovitex 2s
Axogen $153.05 2020-2023 Avance Nerve Graft
Depuy Synthes Sales INC. $140.58 2023 Matrixorthognathic, Matrixrib, Zipfix
Progenics Pharmaceuticals, INC. $109.09 2023 Pylarify
Sientra, INC. $47.50 2020
Musculoskeletal Transplant Foundation INC. $31.25 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Morgan E Norris

$1,400.32

in general payments reported 2019-2025

Years
2019-2024
Top company
Mentor Worldwide LLC

https://glasscript.com/doctor/222844/morgan-e-norris

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.